Seeking value through product alliances
Proteostasis Therapeutics pursues both in-licensing and out-licensing opportunities where our technology and expertise can be applied to provide unique insights and a competitive edge in development.
- To date, we have established collaborations with Astellas Pharma and the Cystic Fibrosis Foundation Therapeutics (CFFT)
The collaboration with Astellas Pharma (TYO:4503), which began in November 2014, is a worldwide collaboration to research and develop therapeutic candidates that modulate the Unfolded Protein Response (UPR). This collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. The companies will conduct discovery, screening, and pre-clinical research to identify lead compounds for clinical development.
The collaboration with CFFT, which began in May 2012, is focused on the research, development, and commercialization of therapies to treat patients with a ΔF508 CFTR mutation by identifying small molecule modulators of protein homeostasis to correct the folding, trafficking, and function of ΔF508 CFTR.
Strength through partnership
Our approach offers potential partners both the ability to explore novel biology as well as complement pre-existing research efforts. Therapeutic candidates identified with our DRT™ platform modulate protein folding, trafficking, and clearance pathways and, therefore, create the potential for broader applicability in the treatment of human disease.
The Proteostasis Therapeutics DRT™ platform can directly generate therapeutic candidates or support existing discovery programs using either phenotypic screens or screens involving specific molecular targets.
For information regarding partnering opportunities with Proteostasis Therapeutics, please contact Business Development at firstname.lastname@example.org.